Frontier Wealth Management LLC increased its position in Pfizer Inc. (NYSE:PFE) by 67.5% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 86,419 shares of the biopharmaceutical company’s stock after buying an additional 34,837 shares during the period. Frontier Wealth Management LLC’s holdings in Pfizer were worth $2,807,000 at the end of the most recent quarter.
A number of other institutional investors also recently made changes to their positions in the company. State Street Corp boosted its position in Pfizer by 3.5% in the fourth quarter. State Street Corp now owns 320,794,199 shares of the biopharmaceutical company’s stock valued at $10,419,393,000 after buying an additional 10,838,463 shares during the period. Northern Trust Corp boosted its position in Pfizer by 0.7% in the third quarter. Northern Trust Corp now owns 82,281,610 shares of the biopharmaceutical company’s stock valued at $2,786,877,000 after buying an additional 592,775 shares during the period. LSV Asset Management boosted its position in Pfizer by 0.7% in the third quarter. LSV Asset Management now owns 35,329,679 shares of the biopharmaceutical company’s stock valued at $1,196,616,000 after buying an additional 260,500 shares during the period. Fisher Asset Management LLC boosted its position in Pfizer by 0.4% in the third quarter. Fisher Asset Management LLC now owns 31,836,368 shares of the biopharmaceutical company’s stock valued at $1,078,298,000 after buying an additional 111,838 shares during the period. Finally, Nordea Investment Management AB boosted its position in Pfizer by 2.8% in the third quarter. Nordea Investment Management AB now owns 28,377,352 shares of the biopharmaceutical company’s stock valued at $961,141,000 after buying an additional 785,387 shares during the period. 69.53% of the stock is currently owned by institutional investors and hedge funds.
Pfizer Inc. (NYSE:PFE) traded down 0.30% during mid-day trading on Friday, reaching $33.64. The company had a trading volume of 25,416,204 shares. The firm has a market capitalization of $200.22 billion, a PE ratio of 28.68 and a beta of 0.94. Pfizer Inc. has a 52 week low of $29.83 and a 52 week high of $37.39. The stock’s 50-day moving average price is $34.16 and its 200 day moving average price is $32.82. Pfizer also was the target of unusually large options trading activity on Tuesday. Stock investors acquired 976 call options on the company. This is an increase of 131% compared to the typical volume of 422 call options.
Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, January 31st. The biopharmaceutical company reported $0.47 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.50 by $0.03. Pfizer had a return on equity of 23.18% and a net margin of 13.50%. The business had revenue of $13.60 billion for the quarter, compared to analysts’ expectations of $13.64 billion. During the same period last year, the business earned $0.53 earnings per share. The company’s revenue for the quarter was down 3.0% on a year-over-year basis. On average, equities research analysts predict that Pfizer Inc. will post $2.55 EPS for the current year.
WARNING: “Pfizer Inc. (PFE) Stake Increased by Frontier Wealth Management LLC” was posted by Community Financial News and is the property of of Community Financial News. If you are viewing this article on another site, it was illegally copied and reposted in violation of US & international trademark & copyright laws. The correct version of this article can be read at https://www.com-unik.info/2017/04/21/frontier-wealth-management-llc-boosts-stake-in-pfizer-inc-pfe-updated-updated.html.
Several research firms recently weighed in on PFE. Deutsche Bank AG restated a “buy” rating and set a $40.00 price target on shares of Pfizer in a research report on Thursday, February 16th. Jefferies Group LLC set a $34.00 price target on Pfizer and gave the company a “neutral” rating in a research report on Thursday, March 9th. Sanford C. Bernstein set a $35.00 price target on Pfizer and gave the company a “buy” rating in a research report on Monday, March 13th. Vetr lowered Pfizer from a “strong-buy” rating to a “buy” rating and set a $35.83 price target on the stock. in a research report on Wednesday, January 18th. Finally, Credit Suisse Group AG set a $38.00 price target on Pfizer and gave the company a “buy” rating in a research report on Monday, March 13th. Thirteen investment analysts have rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the stock. Pfizer presently has an average rating of “Hold” and an average target price of $37.57.
In other Pfizer news, insider Mikael Dolsten sold 30,970 shares of Pfizer stock in a transaction that occurred on Thursday, March 2nd. The shares were sold at an average price of $34.51, for a total value of $1,068,774.70. Following the completion of the sale, the insider now directly owns 64,719 shares of the company’s stock, valued at approximately $2,233,452.69. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Charles H. Hill sold 36,000 shares of Pfizer stock in a transaction that occurred on Thursday, March 9th. The stock was sold at an average price of $34.07, for a total transaction of $1,226,520.00. Following the completion of the sale, the insider now directly owns 57,329 shares of the company’s stock, valued at $1,953,199.03. The disclosure for this sale can be found here. Over the last three months, insiders have sold 71,470 shares of company stock valued at $2,449,150. Corporate insiders own 0.07% of the company’s stock.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
What are top analysts saying about Pfizer Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Pfizer Inc. and related companies.